Literature DB >> 18676772

Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

Masood A Shammas1, Aamer Qazi, Ramesh B Batchu, Robert C Bertheau, Jason Y Y Wong, Manjula Y Rao, Madhu Prasad, Diptiman Chanda, Selvarangan Ponnazhagan, Kenneth C Anderson, Christopher P Steffes, Nikhil C Munshi, Immaculata De Vivo, David G Beer, Sergei Gryaznov, Donald W Weaver, Raj K Goyal.   

Abstract

PURPOSE: The aims of this study were to investigate telomere function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of telomerase inhibition in cancer cells in vitro and in vivo. EXPERIMENTAL
DESIGN: Epithelial cells were purified from surgically resected esophagi. Telomerase activity was measured by modified telomeric repeat amplification protocol and telomere length was determined by real-time PCR assay. To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific telomerase inhibitor (GRN163L) and live cell number was determined weekly. Apoptosis was evaluated by Annexin labeling and senescence by beta-galactosidase staining. For in vivo studies, severe combined immunodeficient mice were s.c. inoculated with adenocarcinoma cells and following appearance of palpable tumors, injected i.p. with saline or GRN163L.
RESULTS: Telomerase activity was significantly elevated whereas telomeres were shorter in BEAC cells relative to normal esophageal epithelial cells. The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis. GRN163L-induced cell death could also be expedited by addition of the chemotherapeutic agents doxorubicin and ritonavir. Finally, the treatment with GRN163L led to a significant reduction in tumor volume in a subcutaneous tumor model.
CONCLUSIONS: We show that telomerase activity is significantly elevated whereas telomeres are shorter in BEAC and suppression of telomerase inhibits proliferation of adenocarcinoma cells both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676772      PMCID: PMC2705940          DOI: 10.1158/1078-0432.CCR-08-0473

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  69 in total

1.  Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions.

Authors:  C Bachor; O A Bachor; P Boukamp
Journal:  J Cancer Res Clin Oncol       Date:  1999 Aug-Sep       Impact factor: 4.553

Review 2.  Telomere dynamics: the means to an end.

Authors:  M Matulić; M Sopta; I Rubelj
Journal:  Cell Prolif       Date:  2007-08       Impact factor: 6.831

3.  Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991.

Authors:  Hiroyuki Seimiya; Tomoko Oh-hara; Tsuneji Suzuki; Imad Naasani; Toshiyuki Shimazaki; Katsutoshi Tsuchiya; Takashi Tsuruo
Journal:  Mol Cancer Ther       Date:  2002-07       Impact factor: 6.261

4.  N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.

Authors:  B S Herbert; B G Sanders; K Kline
Journal:  Nutr Cancer       Date:  1999       Impact factor: 2.900

5.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Authors:  G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

6.  Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  Jill Y Barclay; Alan Morris; Chuka U Nwokolo
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 2.566

7.  Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.

Authors:  Masaharu Akiyama; Teru Hideshima; Masood A Shammas; Toshiaki Hayashi; Makoto Hamasaki; Yu-Tzu Tai; Paul Richardson; Sergei Gryaznov; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

8.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

9.  Telomerase activity: a prevalent marker of malignant human prostate tissue.

Authors:  H J Sommerfeld; A K Meeker; M A Piatyszek; G S Bova; J W Shay; D S Coffey
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

10.  DNA index determination with Automated Cellular Imaging System (ACIS) in Barrett's esophagus: comparison with CAS 200.

Authors:  Qin Huang; Chenggong Yu; Michael Klein; James Fang; Raj K Goyal
Journal:  BMC Clin Pathol       Date:  2005-08-12
View more
  20 in total

Review 1.  Immunosenescence and rheumatoid arthritis: does telomere shortening predict impending disease?

Authors:  Karen H Costenbader; Jennifer Prescott; Robert Y Zee; Immaculata De Vivo
Journal:  Autoimmun Rev       Date:  2011-05-07       Impact factor: 9.754

Review 2.  Therapeutic targeting of gastrointestinal cancer stem cells.

Authors:  Jonathan Stem; John C Flickinger; Dante Merlino; Ellen M Caparosa; Adam E Snook; Scott A Waldman
Journal:  Regen Med       Date:  2019-04-26       Impact factor: 3.806

Review 3.  Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.

Authors:  Nina Frey; Sascha Venturelli; Lars Zender; Michael Bitzer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-29       Impact factor: 46.802

4.  Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth.

Authors:  Jagannath Pal; Mariateresa Fulciniti; Puru Nanjappa; Leutz Buon; Yu-Tzu Tai; Pierfrancesco Tassone; Nikhil C Munshi; Masood A Shammas
Journal:  Cancer Genomics Proteomics       Date:  2012 Mar-Apr       Impact factor: 4.069

Review 5.  Is telomerase a viable target in cancer?

Authors:  C M Buseman; W E Wright; J W Shay
Journal:  Mutat Res       Date:  2011-07-23       Impact factor: 2.433

Review 6.  Telomeres, lifestyle, cancer, and aging.

Authors:  Masood A Shammas
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-01       Impact factor: 4.294

Review 7.  Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target.

Authors:  Jagannath Pal; Jason S Gold; Nikhil C Munshi; Masood A Shammas
Journal:  Transl Res       Date:  2013-10-01       Impact factor: 7.012

8.  Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.

Authors:  Jurjen J Boonstra; Ronald van Marion; David G Beer; Lin Lin; Paula Chaves; Catarina Ribeiro; A Dias Pereira; Lúcia Roque; S Jane Darnton; Nasser K Altorki; David S Schrump; David S Klimstra; Laura H Tang; James R Eshleman; Hector Alvarez; Yutaka Shimada; Herman van Dekken; Hugo W Tilanus; Winand N M Dinjens
Journal:  J Natl Cancer Inst       Date:  2010-01-14       Impact factor: 13.506

9.  Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.

Authors:  Xiaoli Wang; Cing Siang Hu; Bruce Petersen; Jiajing Qiu; Fei Ye; Jane Houldsworth; Kevin Eng; Fei Huang; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-09-25

10.  Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome.

Authors:  J Pal; R Bertheau; L Buon; A Qazi; R B Batchu; S Bandyopadhyay; R Ali-Fehmi; D G Beer; D W Weaver; R J Shmookler Reis; R K Goyal; Q Huang; N C Munshi; M A Shammas
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.